206 related articles for article (PubMed ID: 9136983)
1. Activation of FGF receptors by mutations in the transmembrane domain.
Li Y; Mangasarian K; Mansukhani A; Basilico C
Oncogene; 1997 Mar; 14(12):1397-406. PubMed ID: 9136983
[TBL] [Abstract][Full Text] [Related]
2. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
[TBL] [Abstract][Full Text] [Related]
3. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia.
Naski MC; Wang Q; Xu J; Ornitz DM
Nat Genet; 1996 Jun; 13(2):233-7. PubMed ID: 8640234
[TBL] [Abstract][Full Text] [Related]
4. Heparan sulfate fibroblast growth factor receptor complex: structure-function relationships.
McKeehan WL; Kan M
Mol Reprod Dev; 1994 Sep; 39(1):69-81; discusison 81-2. PubMed ID: 7999363
[TBL] [Abstract][Full Text] [Related]
5. Amino acid residues which distinguish the mitogenic potentials of two FGF receptors.
Wang JK; Goldfarb M
Oncogene; 1997 Apr; 14(15):1767-78. PubMed ID: 9150382
[TBL] [Abstract][Full Text] [Related]
6. Ligand-independent activation of tyrosine kinase in fibroblast growth factor receptor 1 by fusion with beta-galactosidase.
Kouhara H; Kurebayashi S; Hashimoto K; Kasayama S; Koga M; Kishimoto T; Sato B
Oncogene; 1995 Jun; 10(12):2315-22. PubMed ID: 7784079
[TBL] [Abstract][Full Text] [Related]
7. Ligand-independent activation of fibroblast growth factor receptor-2 by carboxyl terminal alterations.
Lorenzi MV; Castagnino P; Chen Q; Chedid M; Miki T
Oncogene; 1997 Aug; 15(7):817-26. PubMed ID: 9266968
[TBL] [Abstract][Full Text] [Related]
8. Mutation associated with Crouzon syndrome causes ligand-independent dimerization and activation of FGF receptor-2.
Mangasarian K; Li Y; Mansukhani A; Basilico C
J Cell Physiol; 1997 Jul; 172(1):117-25. PubMed ID: 9207932
[TBL] [Abstract][Full Text] [Related]
9. Direct FGF receptor 1 activation through an anti-idiotypic strategy mimicks the biological activity of FGF-2 and inhibits the progression of the bladder carcinoma derived from NBT-II cells.
Malavaud B; Pedron S; Sordello S; Mazerolles C; Billottet C; Thiery JP; Jouanneau J; Plouët J
Oncogene; 2004 Sep; 23(40):6769-78. PubMed ID: 15273729
[TBL] [Abstract][Full Text] [Related]
10. Activation of fibroblast growth factor (FGF) receptors by recombinant human FGF-5.
Clements DA; Wang JK; Dionne CA; Goldfarb M
Oncogene; 1993 May; 8(5):1311-6. PubMed ID: 8386828
[TBL] [Abstract][Full Text] [Related]
11. Common and specific determinants for fibroblast growth factors in the ectodomain of the receptor kinase complex.
Wang F; Lu W; McKeehan K; Mohamedali K; Gabriel JL; Kan M; McKeehan WL
Biochemistry; 1999 Jan; 38(1):160-71. PubMed ID: 9890894
[TBL] [Abstract][Full Text] [Related]
12. The Ser252Trp fibroblast growth factor receptor-2 (FGFR-2) mutation induces PKC-independent downregulation of FGFR-2 associated with premature calvaria osteoblast differentiation.
Lemonnier J; Delannoy P; Hott M; Lomri A; Modrowski D; Marie PJ
Exp Cell Res; 2000 Apr; 256(1):158-67. PubMed ID: 10739663
[TBL] [Abstract][Full Text] [Related]
13. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.
Panek RL; Lu GH; Dahring TK; Batley BL; Connolly C; Hamby JM; Brown KJ
J Pharmacol Exp Ther; 1998 Jul; 286(1):569-77. PubMed ID: 9655904
[TBL] [Abstract][Full Text] [Related]
14. Parathyroid hormone regulates the expression of fibroblast growth factor-2 mRNA and fibroblast growth factor receptor mRNA in osteoblastic cells.
Hurley MM; Tetradis S; Huang YF; Hock J; Kream BE; Raisz LG; Sabbieti MG
J Bone Miner Res; 1999 May; 14(5):776-83. PubMed ID: 10320526
[TBL] [Abstract][Full Text] [Related]
15. Docking protein SNT1 is a critical mediator of fibroblast growth factor signaling during Xenopus embryonic development.
Akagi K; Kyun Park E; Mood K; Daar IO
Dev Dyn; 2002 Mar; 223(2):216-28. PubMed ID: 11836786
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor-1 transcriptionally induces membrane type-1 matrix metalloproteinase expression in prostate carcinoma cell line.
Udayakumar TS; Nagle RB; Bowden GT
Prostate; 2004 Jan; 58(1):66-75. PubMed ID: 14673954
[TBL] [Abstract][Full Text] [Related]
17. A novel type I fibroblast growth factor receptor activates mitogenic signaling in the absence of detectable tyrosine phosphorylation of FRS2.
Lopez ME; Korc M
J Biol Chem; 2000 May; 275(21):15933-9. PubMed ID: 10748122
[TBL] [Abstract][Full Text] [Related]
18. Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation.
Freeman KW; Gangula RD; Welm BE; Ozen M; Foster BA; Rosen JM; Ittmann M; Greenberg NM; Spencer DM
Cancer Res; 2003 Oct; 63(19):6237-43. PubMed ID: 14559809
[TBL] [Abstract][Full Text] [Related]
19. Rapid tumor development and potent vascularization are independent events in carcinoma producing FGF-1 or FGF-2.
Billottet C; Janji B; Thiery JP; Jouanneau J
Oncogene; 2002 Nov; 21(53):8128-39. PubMed ID: 12444548
[TBL] [Abstract][Full Text] [Related]
20. A role for extracellular and transmembrane domains of Sef in Sef-mediated inhibition of FGF signaling.
Kovalenko D; Yang X; Chen PY; Nadeau RJ; Zubanova O; Pigeon K; Friesel R
Cell Signal; 2006 Nov; 18(11):1958-66. PubMed ID: 16603339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]